BCL2 and melanoma: In the original research published in 2007 by Mena S. et al., “Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease” [122], the in vivo effects of the combination of GSH and Bcl-2 depletion with various anticancer treatments (such as paclitaxel, X-rays, tumor necrosis factor-α, and IFN-γ) were examined.